EQL Pharma enters into a strategic agreement with Cadila Pharmaceuticals Limited

Translation of Press release published in Swedish 2015-09-22EQL Pharma AB has today, entered into a strategic agreement with Cadila Pharmaceuticals Limited (Cadila Pharma). According to the agreement, EQL Pharma will: · Issue 6.5 million shares to Cadila Pharma at a subscription price of SEK 5 per share, for a total investment by Cadila Pharma of SEK 32.5m. The share price represents a premium of 5% as compared to the last 100 days of trading from the date of first decision, August 25, 2015. · Issue 2 million warrants to Cadila Pharma with a strike price of SEK 6.5 and